The heart is a muscle that never stops working, and like all muscle tissue, it depends completely on oxygen for its function and survival. Coronary artery disease, heart failure, and cardiac events all involve impaired oxygen delivery to heart muscle. Hyperbaric oxygen therapy (HBOT) has been studied as a potential adjunct for cardiac conditions since the 1960s, and a new wave of research is producing interesting findings, particularly around heart failure and post-infarction recovery. The evidence is not yet strong enough for mainstream adoption, but it’s worth understanding clearly.
How Oxygen Therapy Relates to Heart Disease
Cardiovascular disease fundamentally reduces oxygen delivery to the heart muscle (myocardium). In coronary artery disease, narrowed arteries limit blood flow. In heart failure, reduced cardiac output affects perfusion throughout the body including to the heart itself. When oxygen supply falls below demand, myocardial function deteriorates and cells begin to die.
HBOT’s ability to dramatically increase plasma oxygen concentrations, bypassing hemoglobin-based delivery systems, makes it theoretically attractive for cardiac conditions. But the heart is also sensitive to excess oxygen (hyperoxia can cause vasoconstriction in normal coronary arteries), which is why HBOT for cardiac conditions requires careful approach rather than simple application.
2025 Meta-Analysis (Br J Cardiol): HBOT improved LVEF, LVEDV, and LVESV in coronary artery disease patients post-reperfusion.2 Cochrane Review (PMC8101090): potential ACS benefits, data limited.1 HOT-MI study: improved LVEF in STEMI patients.3
Meta-analysis, 2025
HBOT and Acute Myocardial Infarction
Some of the earliest cardiac HBOT research examined its use during or immediately after heart attack. Laboratory and early clinical studies showed that HBOT during the acute phase of myocardial infarction could reduce infarct size, improve contractile function in the surviving myocardium, and reduce the zone of ischemic but potentially salvageable heart muscle (the ischemic penumbra).
The HOTICO trial (1995) and subsequent studies showed some benefit in functional outcomes when HBOT was used in the acute phase.1 HBOT has not been incorporated into standard acute MI management protocols, partly because catheterization-based reperfusion therapy (stenting) is so effective and immediately accessible in modern hospitals. Coordinating HBOT with emergency cardiac care is logistically challenging.
HBOT and Heart Failure
Chronic heart failure is characterized by the heart’s reduced ability to pump adequately, leading to fluid accumulation, fatigue, and reduced exercise tolerance. Several Israeli and European studies have examined HBOT in heart failure patients with reduced ejection fraction.
A 2011 study by Yogaratnam and colleagues found that a course of HBOT in heart failure patients produced significant improvements in left ventricular ejection fraction, six-minute walk distance, and quality of life scores. These improvements persisted at six-month follow-up. The proposed mechanisms include improved myocardial oxygenation, anti-inflammatory effects reducing the inflammatory component of heart failure progression, and angiogenesis in ischemic myocardium.
These results are promising but come from small studies. Large randomized controlled trials validating HBOT as a standard heart failure adjunct have not been completed.
Cardiovascular Effects of HBOT
Blood Pressure Effects
HBOT at therapeutic pressures (2.0 ATA and above) produces a mild, temporary reduction in heart rate and a small increase in peripheral vascular resistance due to oxygen-induced vasoconstriction. Net blood pressure effects are generally modest and well-tolerated. In hypertensive patients, monitoring during sessions is appropriate.
Anti-Atherosclerotic Effects?
Some research has examined whether HBOT’s anti-inflammatory effects might reduce atherosclerosis progression. This is speculative territory with limited evidence. HBOT is not supported as an atherosclerosis treatment.
Angiogenesis
HBOT’s ability to stimulate new blood vessel growth is well-documented in wound healing contexts. Whether this same angiogenic effect occurs in myocardial tissue and provides functional benefit in heart disease is an open research question. Some animal studies show angiogenesis in ischemic myocardium after HBOT, but this hasn’t been clearly demonstrated in human cardiac studies.
Important Safety Considerations
HBOT is not appropriate for all cardiac patients. The pressurization process and physical demands of chamber entry are not suitable for patients with severe cardiac instability, uncontrolled arrhythmias, or decompensated heart failure. Ejection fraction thresholds and stability criteria should be discussed with your cardiologist before any HBOT consideration.
The side effects and contraindications guide covers cardiac-specific considerations. The session guide explains what physiological demands the session process involves.
HBOT as Part of Cardiac Rehabilitation
Some centers have explored HBOT as a complement to standard cardiac rehabilitation programs. The premise is that improved oxygenation and reduced inflammation may allow patients to engage more effectively in exercise-based rehabilitation and recover cardiac function more quickly after events. This is speculative as a formal recommendation but is an active area of investigation.
For patients with diabetes who also have heart disease (a very common combination), HBOT’s documented benefits for diabetic vascular complications may provide additional cardiac-adjacent benefit. The diabetes and HBOT article covers the vascular aspects of diabetic complications.
HBOT After Cardiac Surgery
Cardiac surgery creates significant physiological stress: the heart-lung bypass machine used in open-heart procedures can cause systemic inflammatory responses, micro-emboli, and temporary cognitive effects (“pump head”). The post-surgical recovery period involves healing of the sternotomy (breast bone cut) and all surgical incisions, alongside cardiac function restoration. HBOT has been explored as an adjunct in this context, theoretically benefiting from its anti-inflammatory effects and support for tissue healing. Evidence is limited to small studies, and HBOT is not a standard post-cardiac surgery protocol. Patients with delayed sternal healing or wound complications might be the subgroup where HBOT has the most plausible role.
Peripheral Vascular Disease and the Heart
Many patients with heart disease also have peripheral vascular disease (PAD), reduced blood flow to the legs and feet. HBOT for PAD-related wound complications (non-healing foot ulcers from arterial insufficiency) is a related but distinct application from cardiac HBOT. The mechanisms are the same: improving oxygen delivery to ischemic tissue and stimulating angiogenesis. Patients with concurrent heart disease receiving HBOT for PAD complications require cardiac monitoring during sessions and clearance from their cardiologist. The cardiac and vascular dimensions often need to be managed together rather than in isolation.
Lifestyle Factors That Influence Both Heart Health and HBOT Response
Smoking, which dramatically impairs vascular health and angiogenesis, is the single lifestyle factor most likely to reduce HBOT’s effectiveness for cardiac and vascular applications. Smokers have significantly worse outcomes from HBOT in wound healing studies, and the same impairment in angiogenic response applies to cardiac applications. If you’re considering HBOT for any cardiovascular condition and are still smoking, cessation is the highest-value intervention available, both for your cardiovascular health and for improving any potential HBOT response. The wound healing article covers smoking’s impact on HBOT outcomes in more detail.
HBOT in the Context of Heart Failure Management
Heart failure management has advanced substantially with medical therapy: ACE inhibitors/ARBs, beta-blockers, SGLT2 inhibitors, and MRAs have all demonstrated mortality benefit in specific heart failure populations. Device therapy (ICD, CRT) provides additional benefit for eligible patients. Against this background of effective medical management, the incremental benefit of HBOT needs to be evaluated: is there a role for HBOT in patients who are already on optimal medical therapy and still have significant symptoms or reduced function?
The small studies showing HBOT benefit in heart failure have not controlled for optimal medical management, meaning it’s unclear whether improvements seen with HBOT are additive to modern heart failure therapy or primarily relevant in undertreated populations. A heart failure cardiologist who is aware of your full medication regimen and current functional status is the appropriate person to evaluate whether HBOT makes sense as an adjunct in your specific situation.
Pulmonary Hypertension and HBOT
Pulmonary hypertension, elevated pressure in the pulmonary circulation, is a potential concern in HBOT for some cardiac patients. The pressurization and oxygen exposure in HBOT can theoretically affect pulmonary vascular resistance. For patients with known pulmonary hypertension, evaluation by a cardiologist or pulmonologist familiar with this condition is mandatory before HBOT for any indication. Severe or uncontrolled pulmonary hypertension may be a contraindication. Mild or well-managed pulmonary hypertension in stable patients may not be a barrier to HBOT for appropriately selected indications.
Frequently Asked Questions
Can HBOT replace cardiac medication?
No. There is no evidence that HBOT substitutes for any established cardiac medication, whether for heart failure, arrhythmia, or coronary artery disease. It is a potential adjunct, not an alternative.
Is HBOT safe after a heart attack?
In stable post-MI patients, HBOT may be considered with cardiologist clearance. In the acute or immediate post-MI period, it is not generally used outside of specific research protocols. Stability of the cardiac condition is the prerequisite for any HBOT consideration.
Does HBOT affect heart rate?
Yes, modestly. Therapeutic HBOT typically produces a mild reduction in heart rate during the session, related to the cardiovascular reflex response to hyperoxia. This is well-tolerated in most patients but requires monitoring in those with arrhythmias or pacemakers. Pacemaker compatibility with the hyperbaric environment should be confirmed before treatment.
Where can I find a cardiologist who is familiar with HBOT?
Major academic medical centers and hospitals with hyperbaric medicine programs are the most likely places to find cardiologists and hyperbaric physicians who communicate effectively about cardiac patients. The UHMS maintains a directory of accredited hyperbaric programs at uhms.org.
References
- Cochrane Review. “Hyperbaric oxygen therapy for acute coronary syndrome.” PMC8101090. PMC8101090
- 2025 Meta-Analysis. “Effect of HBOT on LV function in CAD patients after reperfusion.” Br J Cardiol.
- HOT-MI Study. Hyperbaric Oxygen and Thrombolysis in Myocardial Infarction. Improved LVEF in STEMI.
- StatPearls. “Hyperbaric Cardiovascular Effects.” NCBI NBK482231. NBK482231
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
